Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

Dexmedetomidine shows favorable pharmacokinetics for long-term sedation in renal failure patients

April 2, 2009

Acorda Therapeutics receives FDA refuse to file letter for Fampridine-SR NDA

April 1, 2009

Shire and GlaxoSmithKline to co-promote Vyvanse for adult ADHD

April 1, 2009

Sepracor submits NDA to FDA for Stedesa as adjunctive epilepsy treatment

April 1, 2009

Newron randomizes first patients in phase IIb/III ralfinamide study in pain

April 1, 2009

ExonHit expands neurological research activities to include epilepsy

April 1, 2009

Roche presents novel TAAR1 ligands

April 1, 2009

5-HT6 antagonist AVN-322 deemed a candidate for neurodegenerative diseases

April 1, 2009

Novel metabotropic glutamate receptor agonists display antiparkinsonian effects in vivo

April 1, 2009

AstraZeneca to meet with FDA Psychopharmacologic Drugs Advisory Committee

March 31, 2009

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 4, 2026.
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...
CROI 2026 highlights depression and cognitive vulnerability in HIV
BioWorld
The effects of aging pose an additional challenge for people with HIV due to the neurological and psychological consequences that persist despite antiretroviral...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
Slate Medicines launches with focus on headache disorders
BioWorld Science
Slate Medicines Inc. has launched with $130 million in series A financing and a focus on advancing next-generation therapeutics for migraine and other headache...